EAP 2021 Virtual Congress and MasterCourse

Childhood Tuberculosis and Treatment Outcome in Tertiary Referral Hospital in Malaysia

Mohamad Azlan Bin Hamdan Sitti Sulhoon Mohamed Thahira Jamal Mohamed
Paediatric Department, Paediatric Infectious Disease Unit, Women and Children Hospital Kuala Lumpur (WCHKL), Malaysia

Background :Tuberculosis (TB) contributes a significant morbidity and mortality in children worldwide.

Objectives :The study objective was to described the characteristics and treatment outcomes of children with TB in Women and Children Hospital Kuala Lumpur (WCHKL).

Method :A retrospective cross -sectional study conducted in paediatric infectious diseases out-patient clinic using a newly formed TB registry. All children (below 18 years) diagnosed TB and follow-up from July 2019 to August 2020 are included. Demographic and clinical characteristic as well as treatment outcome were assessed.

Results :A total of 45 children were enrolled in this registry (median age: 5 years) and 11(24.4%) of them were excluded following diagnosis of latent TB infection. The diagnosis of TB disease was made based on either microbiologically proven or non-microbiologically proven in the presence of a clinical diagnosis of TB or suggestive radiographic findings. Out of 34 children, more than half were female (55.9%) with children below 5 years of age make up 44.1% (15/34). The distribution of TB types were as follows: pulmonary TB 23.5%, extrapulmonary TB 17.6% and disseminated TB 55.9%. Four children (11.9%) were immunocompromised and one of them had Wiskot-Aldrich syndrome . Only 2 children (5.8%) had drug induced liver injury .One child with disseminated disease had treatment interruption needing re-treatment. Median duration of clinic follow-up were 12 months and none defaulted. Twelve children (35.8%) had completed the treatment. No mortality from TB was recorded

Conclusion :TB in children when diagnosed early improve mortality and children below 5 years of age remains at risk. Follow-up during each phase of treatment is needed to look at compliant and drug related adverse events even when it is rare.









Powered by Eventact EMS